Pharmacotherapy of Alzheimer's disease

Psychiatry

Volumn 7, Issue 1, 2008, Pages 9-14

  Wilkinson, David ^a  

^a MOORGREEN HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; cholinesterase inhibitors; donepezil; galantamine; memantine; rivastigmine

Indexed keywords

4 AMINOBUTYRIC ACID; BESIPIRDINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; FLURBIPROFEN; GALANTAMINE; GLITAZONE DERIVATIVE; GLUTAMIC ACID; HOMOTAURINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LINOPIRDINE; MEMANTINE; MILAMELINE; NEUROPEPTIDE Y; NICOTINIC AGENT; PLACEBO; RIVASTIGMINE; SEROTONIN; SOMATOSTATIN; TACRINE; TALSACLIDINE; XANOMELINE;

AGITATION; ALERTNESS; ALZHEIMER DISEASE; ANOREXIA; ATTENTION; CAREGIVER; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DIARRHEA; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; DREAMING; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; LANGUAGE; MENTAL DISEASE; MULTIINFARCT DEMENTIA; NAUSEA; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SEDATION; SIDE EFFECT; SLEEP DISORDER; SYMPTOM; VOMITING;

EID: 37449033897     PISSN: 14761793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mppsy.2007.11.005     Document Type: Review

References (9)

1. Holmes C., and Lovestone S. Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Age Ageing 32 (2003) 200-204
2. Mohs R.C., Doody R.S., Morris J.C., et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57 (2001) 481-488
3. Winblad B., Engedal K., Soininen H., et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57 (2001) 489-495
4. Holmes C., Wilkinson D., Dean C., et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer's Disease. Neurology 63 (2004) 214-219
5. Corey-Bloom J., Anand R., and Veach J. A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1 (1998) 55-65
6. Emre M., Aarsland D., Albanese A., et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351 (2004) 2509-2518
7. Raskind M.A., Peskind E.R., Wessel T., et al. Galantamine in AD. A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 54 (2000) 2261-2268
8. Peskin E.R., Potkin S.G., Pomara N., et al. Memantine treatment in mild-to-moderate Alzheimer's disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14 (2006) 704-715
9. Tariot P.N., Farlow M.R., Grossberg G.T., et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291 (2004) 317-324